The U.S. Food and Drug Administration has denied approval for PTC Therapeutics' oral medication for a rare genetic disorder ...

Starting oral risdiplam soon after birth may put babies with spinal muscular atrophy on the path to normal development, new ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has ...

Infants up to 6 weeks old with genetically diagnosed presymptomatic spinal muscular atrophy (SMA) treated with oral risdiplam ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

The International Progressive MS Alliance announces the launch of its MS Clinical and Imaging Data Resource (CIDR), which ...

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.9, a high estimate of $219.00, and a low estimate of $115.00. This current ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. | Despite missing its primary endpoint in a ...

Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.